Something other than Oncology I suppose. It is so broad. Ultimately none of it really matters what other deals are getting anyway until phase one is under way, and then results. Its not worth much if that result is no good. At ~25c, there isn't much value being ascribed to NYR-PCSK9i upside presently - market just thinks its a bit so so... Which for me I think is great, better entry price now with a lot more upside on successful phase 1.
Test of 25c isn't completely surprising on a TA basis. TA purists would have always been waiting for the 25c support to be tested. And for it to be tested again in the next week or so and bounce back off that back into the prior trading range.
Fundamentally the cap raise was 26c too, so naturally, participants are now at risk of being in the red.
Very interested to see the price action and volume over the next 2 weeks.
NYR Price at posting:
27.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)